Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality
worldwide. Its complexity is influenced by various signal transduction networks that govern …

Simple Summary Cancer metastasis is often associated with a dismal prognosis for the
patient. It is, therefore, crucial to understand the mechanisms behind the cascade of events …

Background HER2 amplification has been identified in 2–3% of patients with colorectal
cancer, although there are currently no approved HER2-targeted therapies for colorectal …

Abstract DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial
assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2 …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Despite recent advances in the management of colorectal cancer, metastatic disease
remains challenging, and patients are rarely cured. However, a better understanding of the …

Effective antitumour immunity depends on the orchestration of potent T cell responses
against malignancies. Regression of human cancers has been induced by immune …

HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers.
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

HER2 targeted therapies have significantly improved prognosis of HER2-positive breast and
gastric cancer. HER2 overexpression and mutation is the pathogenic driver in non-small cell …